Suehiro Yutaka, Suenaga Shigeyuki, Kunimune Yuki, Yada Shoko, Hamamoto Kaori, Tsuyama Takanori, Amano Shogo, Matsui Hiroto, Higaki Shingo, Fujii Ikuei, Suzuki Chieko, Hoshida Tomomi, Matsumoto Toshihiko, Fujimoto Yuko, Kaino Seiji, Shinjo Keiko, Kondo Yutaka, Sakaida Isao, Takami Taro, Nagano Hiroaki, Yamasaki Takahiro
Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Oncology. 2022;100(12):674-684. doi: 10.1159/000527342. Epub 2022 Oct 14.
We previously developed a novel methylation assay, the combined restriction digital PCR (CORD) assay, consisting of treatment of DNA with methylation-sensitive restriction enzymes and droplet digital PCR.
In this study, we assessed the diagnostic performance of serum methylated Homeobox A1 (mHOXA1) and methylated somatostatin (mSST) using the CORD assay in combination with CA19-9 for pancreatic cancer using serum samples from 82 healthy individuals, 13 patients with benign pancreatic disease, 3 patients with branched-duct intraductal papillary mucinous neoplasm, and 91 patients with pancreatic cancer.
For the single marker tests, sensitivity for all stages of pancreatic cancer, stage I cancer, and specificity were, respectively, 71.4%, 50.0%, and 94.9% for CA19-9; 51.6%, 68.8%, and 90.8% for mHOXA1; and 50.1%, 68.8%, and 94.9% for mSST. Those for the combined marker tests were, respectively, 86.8%, 81.3%, and 85.7% for combined mHOXA1 and CA19-9; 86.8%, 87.5%, and 89.8% for combined mSST and CA19-9; and 89.0%, 87.5%, and 85.7% for all three markers combined.
The combination of mHOXA1 and mSST with CA19-9 appears to be useful to detect pancreatic cancer even at an early stage.
我们之前开发了一种新型甲基化检测方法，即联合限制性数字PCR（CORD）检测法，该方法包括用甲基化敏感限制性内切酶处理DNA以及液滴数字PCR。
在本研究中，我们使用CORD检测法，结合CA19-9，对来自82名健康个体、13名胰腺良性疾病患者、3名分支导管内乳头状黏液性肿瘤患者和91名胰腺癌患者的血清样本进行检测，以评估血清甲基化同源盒A1（mHOXA1）和甲基化生长抑素（mSST）对胰腺癌的诊断性能。
对于单一标志物检测，CA19-9对胰腺癌各阶段、I期癌症的敏感性及特异性分别为71.4%、50.0%和94.9%；mHOXA1分别为51.6%、68.8%和90.8%；mSST分别为50.1%、68.8%和94.9%。对于联合标志物检测，mHOXA1与CA19-9联合时分别为86.8%、81.3%和85.7%；mSST与CA19-9联合时分别为86.8%、87.5%和89.8%；三种标志物联合时分别为89.0%、87.5%和85.7%。
mHOXA1和mSST与CA19-9联合使用似乎有助于早期检测胰腺癌。
